Register Now
Course Information

An Invitation from Dr. Charis Eng

Dear Colleagues and Friends,

I am pleased to invite you to attend the Genomic Medicine Institute’s International PTEN Symposium: From Patient-Centered Research to Clinical Care. We are planning an engaging day with an emphasis on advances in the diagnosis, management, and treatment of patients with PTEN Hamartoma Tumor Syndrome.

Pier Paolo Pandolfi, MD, PhD, the Director of Cancer Research at Beth Israel Deaconess Medical Center, will deliver the day’s keynote address on PTEN reactivation for tumor prevention and therapy. Other topics include breast cancer risks and decision making, the PTEN pathway in cancer, skin manifestations, neuroimaging findings, and autism. Please refer to the enclosed agenda for more details about this year’s speakers and topics.

I am sure you will enjoy this day of education and discussion centered on our common interests in PTEN patient-centered research and clinical care. A highlight of the day is certain to be our PTEN Patient Panel to hear the unique patient perspective. We will close the day with remarks from myself, Kristin Anthony, President of the PTEN Hamartoma Tumor Syndrome Foundation and Claudio Ales, President of PTEN Italia, both patient advocacy groups, followed by a reception where you’ll have the opportunity to join together with your friends and colleagues.


Charis Eng, MD, PhD
Hardis Chair, Genomic Medicine Institute
Director, Center for Personalized Genetic Healthcare
Medical Director, PTEN/Cowden Multidisciplinary Clinic
Cleveland Clinic


Course Overview

This program, presented by Cleveland Clinic’s Genomic Medicine Institute, will provide the opportunity to review the latest advances in PTEN Hamartoma Tumor Syndrome and offer state-of-the-art information to healthcare providers treating patients with germline PTEN mutations. Expert Cleveland Clinic and external faculty will share case-based presentations and research highlighting the advances of genetics and genomics of PHTS, PTEN signaling pathways and non-human models of PHTS.

Who Should Attend

We invite practitioners and healthcare professionals seeking to learn the latest developments in PTEN management and research, especially providers in Oncology, Internal Medicine and Subspecialties, Pediatrics, Neurology, Dermatology, Endocrinology, Gastroenterology, Nephrology, Urology, and Psychology/Psychiatry. Additionally, trainees and students with an interest in expanding their knowledge of PTEN Hamartoma Tumor Syndrome and the science of PTEN and pathways are encouraged to attend. Patients, families and caregivers are also invited to attend to learn about cutting-edge PTEN research as well as clinical surveillance and management guidelines.

By Attending, You Will Be Able To:

  • Describe current PTEN translational and clinical research
  • Apply information about PHTS diagnosis, screening, surveillance, guidelines, patient needs, clinical features, and coordination of multidisciplinary team care
  • Demonstrate awareness and share education about PHTS, leading to timely diagnosis, appropriate surveillance and improved patient outcomes